Genomma Lab Internacional, S.A.B. de C.V.

Genomma Lab Internacional, S.A.B. de C.V.verified

GNMLF

Price:

$1.07

Market Cap:

$1.09B

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico and internationally. It provides skin care, health and wellness, hair care, pain relief, cough and cold, gastro, sexual health, antiperspirant deodorant, hand sanitizer, isotonic deink, and razor products, as well as analgesics, antifungals, and hemorrhoids. The company offers its products under the Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, U...[Read more]

Industry

Drug Manufacturers - Specialty & Generic

IPO Date

2012-05-04

Stock Exchange

PNK

Ticker

GNMLF

The PE Ratio as of September 2024 (TTM) for Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) is 17.83

According to Genomma Lab Internacional, S.A.B. de C.V.’s latest financial reports and current stock price. The company's current PE Ratio is 17.83. This represents a change of -2161.94% compared to the average of -0.86 of the last 4 quarters.

Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Historical PE Ratio (quarterly & annually)

How has GNMLF PE Ratio performed in the past?

The mean historical PE Ratio of Genomma Lab Internacional, S.A.B. de C.V. over the last ten years is 8.53. The current 17.83 PE Ratio has changed 20.80% with respect to the historical average. Over the past ten years (40 quarters), GNMLF's PE Ratio was at its highest in in the December 2021 quarter at 25.04. The PE Ratio was at its lowest in in the December 2023 quarter at -29.48.

Quarterly (TTM)
Annual

Average

8.53

Median

13.21

Minimum

-14.30

Maximum

24.42

Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Genomma Lab Internacional, S.A.B. de C.V. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 161.54%

Maximum Annual PE Ratio = 24.42

Minimum Annual Increase = -200.82%

Minimum Annual PE Ratio = -14.30

Quarterly (TTM)
Annual
YearPE RatioChange
202313.2113.21%
202211.67-29.74%
202116.6121.11%
202013.72-43.82%
201924.42161.54%
20189.34-35.27%
201714.42-200.82%
2016-14.3016.22%

Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Average PE Ratio

How has GNMLF PE Ratio performed in the past?

The current PE Ratio of Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

13.83

5-year avg

15.93

10-year avg

8.53

Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) PE Ratio vs. Peers

How is GNMLF’s PE Ratio compared to its peers?

Genomma Lab Internacional, S.A.B. de C.V.’s PE Ratio is less than RAMM Pharma Corp. (0), greater than Speakeasy Cannabis Club Ltd. (-0.00), greater than City View Green Holdings Inc. (-1.11), greater than Craftport Cannabis Corp. (-0.01), greater than Hypera S.A. (10.93), greater than Indivior PLC (-9.48), greater than YourWay Cannabis Brands Inc. (0), greater than Cumberland Pharmaceuticals Inc. (-1.77), greater than Orexo AB (publ) (-6.60), greater than Sumitomo Pharma Co., Ltd. (-0.97), greater than Indivior PLC (-9.48), greater than C21 Investments Inc. (-6.77), greater than RavenQuest BioMed Inc. (-0.00), greater than Bhang Inc. (-0.01), greater than Willow Biosciences Inc. (-1.56), greater than Alpha Teknova, Inc. (-5.23), greater than Guardion Health Sciences, Inc. (-2.18), greater than Lifecore Biomedical, Inc. (13.05), greater than Organogenesis Holdings Inc. (-49.69), greater than Petros Pharmaceuticals, Inc. (-0.22),

Build a custom stock screener for Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genomma Lab Internacional, S.A.B. de C.V. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Genomma Lab Internacional, S.A.B. de C.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Genomma Lab Internacional, S.A.B. de C.V.'s PE Ratio?

How is the PE Ratio calculated for Genomma Lab Internacional, S.A.B. de C.V. (GNMLF)?

What is the highest PE Ratio for Genomma Lab Internacional, S.A.B. de C.V. (GNMLF)?

What is the 3-year average PE Ratio for Genomma Lab Internacional, S.A.B. de C.V. (GNMLF)?

What is the 5-year average PE Ratio for Genomma Lab Internacional, S.A.B. de C.V. (GNMLF)?

How does the current PE Ratio for Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) compare to its historical average?